TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29397899

Group type: EXPERIMENTAL
Intervention: 1 g/day sodium benzoate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 g/day sodium benzoate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27659931

Group type: EXPERIMENTAL
Intervention: Neutral-pH, low-GDP peritoneal dialysis solution (balance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional peritoneal dialysis fluid (cPDF)
Number of subjects: 0
Study: 24104055

Group type: EXPERIMENTAL
Intervention: Liking for food at the end of a consumption experience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitigating the decrease in liking from repeated consumption
Number of subjects: 0
Study: 22100003

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Semirigid ureterolithotripsy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Laparoscopic ureterolithotomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 48
Study: 20844595

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg s.c. every other week for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adalimumab and Placebo
Number of subjects: 24
Study: 18927988

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0
Study: 15917949

Group type: EXPERIMENTAL
Intervention: FTY720 (0.25‐2.5 mg/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Mofetil mycophenolate (2 mg/day)
Number of subjects: 23
Study: 12813615

Group type: EXPERIMENTAL
Intervention: Eptifibatide (EP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Abciximab (AB)
Number of subjects: 160
Study: 12584789

Group type: EXPERIMENTAL
Intervention: Jiangya Tongmai Recipe (JYTMR)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Captopril (Control)
Number of subjects: 37
Study: 10511062

Group type: EXPERIMENTAL
Intervention: 400 mg clarithromycin twice a day for 3 days, followed by 20 mg omeprazole
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7742773

Group type: EXPERIMENTAL
Intervention: 10 sec maximal exercise test
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 30 sec maximal exercise test
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 90 sec maximal exercise test
Number of subjects: 7
Study: 2225396

Group type: COMPARATOR
Intervention: Hancock 19-mm modified orifice (MO) valve
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hancock 21-mm valve
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hancock 23-mm MO valve
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hancock 19-mm MO valve
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hancock 21-mm MO valve
Number of subjects: 100
Study: 7050036

Group type: EXPERIMENTAL
Intervention: Misonidazole
Number of subjects: 62

Group type: COMPARATOR
Intervention: Radiotherapy (6 fraction technique)
Number of subjects: 62
Study: 31852462

Group type: EXPERIMENTAL
Intervention: Canned, pre-cooked dry beans (1 cup/day for 6 weeks after a 2-week ramp-up)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual diet without dry beans
Number of subjects: 0
Study: 27993589

Group type: EXPERIMENTAL
Intervention: Fixed-combination travoprost 0.004%/timolol 0.5% (TTFC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Separate containers of travoprost 0.004% and timolol 0.5% (TRAV+TIM)
Number of subjects: 81
Study: 25548798

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 minutes twice a week)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Reference group (lectures)
Number of subjects: 116
Study: 24802019

Group type: EXPERIMENTAL
Intervention: 200 mg FTC capsules alone (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 200 mg FTC combined with 300 mg TDF tablets (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 200 mg FTC plus 300 mg TDF with a high-fat diet (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multiple oral doses of 200 mg FTC capsules (Group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multiple oral doses of 200 mg FTC combined with 300 mg TDF tablets (Group E)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multiple oral doses of 200 mg FTC plus 300 mg TDF with a high-fat diet (Group F)
Number of subjects: 60
Study: 23010779

Group type: EXPERIMENTAL
Intervention: High-fat diets (40% fat, 15% protein)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: High-protein diets (15% fat, 25% protein)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Calorically restricted diets (various macronutrient compositions)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: All four dietary conditions
Number of subjects: 811

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 811
Study: 18706856

Group type: EXPERIMENTAL
Intervention: Sleep Disturbance Scale for Children (SDSC)
Number of subjects: 100
Study: 18091269

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 596

Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 596
Study: 15141265

Group type: EXPERIMENTAL
Intervention: Synchronized nasal intermittent positive pressure ventilation (SNIPPV)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 59
Study: 11964938

Group type: EXPERIMENTAL
Intervention: Random effects models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjects with steeper marker drops
Number of subjects: 0
Study: 9738561

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg
Number of subjects: 531
Study: 8291819

Group type: COMPARATOR
Intervention: Continuous Ambulatory Peritoneal Dialysis with a Y-connector
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Continuous Cyclic Peritoneal Dialysis
Number of subjects: 82
Study: 2544640

Group type: EXPERIMENTAL
Intervention: Bupivacaine (5 mg/ml)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Lidocaine (20 mg/ml)
Number of subjects: 71
Study: 29470950

Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraception (LARC)
Number of subjects: 916

Group type: COMPARATOR
Intervention: Short-acting reversible contraception (SARC) - randomized
Number of subjects: 916

Group type: COMPARATOR
Intervention: Short-acting reversible contraception (SARC) - preference
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraception (LARC) - randomized
Number of subjects: 916
Study: 27431644

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 20770
Study: 24561962

Group type: EXPERIMENTAL
Intervention: +0.5DS for both eyes
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Full correction for hyperopes
Number of subjects: 108

Group type: COMPARATOR
Intervention: No glasses for hyperopes
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Spectacles for myopes
Number of subjects: 108
Study: 22281826

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Pegaptanib (Macugen)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT)
Number of subjects: 122
Study: 20819550

Group type: EXPERIMENTAL
Intervention: 0.3% gatifloxacin ophthalmic gel
Number of subjects: 96

Group type: COMPARATOR
Intervention: 0.3% gatifloxacin ophthalmic solution
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison of gatifloxacin ophthalmic gel vs solution
Number of subjects: 96
Study: 18649049

Group type: COMPARATOR
Intervention: Myocrisin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Auranofin
Number of subjects: 58
Study: 17130189

Group type: EXPERIMENTAL
Intervention: Community center-based resistance training maintenance program (2 times/week for 12 months)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Home-based resistance training maintenance program (2 times/week for 12 months)
Number of subjects: 57
Study: 12795036

Group type: EXPERIMENTAL
Intervention: Wellness intervention (individualized goal setting)
Number of subjects: 57
Study: 10748311

Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9352758

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.0625% + fentanyl 3.3 micrograms/ml infusion (Group EPI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Patient-controlled intravenous morphine analgesia (Group PCA)
Number of subjects: 120
Study: 8403900

Group type: EXPERIMENTAL
Intervention: Dalkon Shield IUD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lippes Loop D or Copper IUDs
Number of subjects: 0
Study: 3536108

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine eight hourly for three weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 3142949

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition (PPN)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 34
Study: 30073793

Group type: EXPERIMENTAL
Intervention: Febuxostat IR 40 mg
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Febuxostat IR 80 mg
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Febuxostat XR 40 mg
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Febuxostat XR 80 mg
Number of subjects: 1790

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1790
Study: 28655620

Group type: EXPERIMENTAL
Intervention: Resealable package
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unresealable package
Number of subjects: 0
Study: 26210304

Group type: EXPERIMENTAL
Intervention: Continuous defocused CO2 laser treatment
Number of subjects: 171

Group type: COMPARATOR
Intervention: Symptomatic conservative treatment (oral salve containing lidocaine hydrochloride or systemic diclofenac)
Number of subjects: 171
Study: 23041585

Group type: COMPARATOR
Intervention: Flat dosing of carboplatin (Arm A)
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: Intrapatient dose escalation of carboplatin (Arm B)
Number of subjects: 964
Study: 21601973

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 33
Study: 19458031

Group type: EXPERIMENTAL
Intervention: Plant sterol esters (2.5 g/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plant stanol esters (2.5 g/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16924445

Group type: EXPERIMENTAL
Intervention: Vector‐Vision navigation system (n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional technique (n=60)
Number of subjects: 120
Study: 12417984

Group type: EXPERIMENTAL
Intervention: Laserneedle stimulation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Manual needle stimulation
Number of subjects: 27
Study: 10560752

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0
Study: 7738618

Group type: EXPERIMENTAL
Intervention: Hormone therapy with megestrol acetate
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hormone therapy with fadrozole
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Low serum c-erbB-2 levels
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Elevated serum c-erbB-2 levels
Number of subjects: 300
Study: 1855082

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte macrophage colony stimulating factor (rhGM‐CSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte macrophage colony stimulating factor (rhGM‐CSF) in patients with marrow graft failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte macrophage colony stimulating factor (rhGM‐CSF) in pediatric patients
Number of subjects: 0
Study: 7323140

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) at four different doses
Number of subjects: 10
Study: 31543299

Group type: EXPERIMENTAL
Intervention: ICG-diode laser treatment (PTT group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (non-PTT teeth)
Number of subjects: 22
Study: 30390647

Group type: EXPERIMENTAL
Intervention: Early mass drug administration (MDA) consisting of 3 rounds of a 3-day course of dihydroartemisinin-piperaquine plus a single low dose of primaquine.
Number of subjects: 1919

Group type: COMPARATOR
Intervention: Deferred mass drug administration (control group).
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Completion of 3 rounds of MDA.
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Early mass drug administration (MDA).
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Adverse events reported by participants.
Number of subjects: 1919
Study: 28557722

Group type: EXPERIMENTAL
Intervention: HS + Preschool Obesity Prevention Series (POPS) + Incredible Years Series (IYS)
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: HS + Preschool Obesity Prevention Series (POPS)
Number of subjects: 697

Group type: COMPARATOR
Intervention: HS
Number of subjects: 697
Study: 26244387

Group type: COMPARATOR
Intervention: Control group (tenofovir/emtricitabine + lopinavir/ritonavir)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: ABC/ddI group (abacavir + didanosine + lopinavir/ritonavir)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: DRV group (tenofovir/emtricitabine + darunavir/ritonavir)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Patients with baseline viral load at least 100,000 copies/ml
Number of subjects: 451
Study: 24089388

Group type: EXPERIMENTAL
Intervention: Valproic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parental assessment
Number of subjects: 0
Study: 21345226

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 354
Study: 18449593

Group type: EXPERIMENTAL
Intervention: Trimebutine (200 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 16513579

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg and hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 17242
Study: 14510746

Group type: EXPERIMENTAL
Intervention: Raftilin HP (5 or 10 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raftilin HP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 0
Study: 11014404

Group type: EXPERIMENTAL
Intervention: Loperamide (16 mg) with quinidine (600 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Loperamide (16 mg) alone
Number of subjects: 8
Study: 9001833

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (5 mL of normal saline)
Number of subjects: 60
Study: 1642346

Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control group, n = 10)
Number of subjects: 20
Study: 6601560

Group type: EXPERIMENTAL
Intervention: 80 mg of 4-aminobenzoic acid (PAB) with meals (240 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Single dose of 80 mg of PAB
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Various doses of PAB divided throughout the day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 80 mg of PAB with meals
Number of subjects: 33
Study: 31743342

Group type: EXPERIMENTAL
Intervention: Video abstracts
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Plain language summaries
Number of subjects: 538

Group type: COMPARATOR
Intervention: Graphical abstracts
Number of subjects: 538

Group type: COMPARATOR
Intervention: Published abstracts
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: All summary types
Number of subjects: 538
Study: 28980294

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) infusion (50 mg/kg) after induction of anaesthesia, with two additional doses on postoperative days 1 and 2.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal saline (placebo) administered during the same time interval as NAC.
Number of subjects: 150

Group type: COMPARATOR
Intervention: NAC group vs placebo group regarding hsCRP levels.
Number of subjects: 150
Study: 27981301

Group type: EXPERIMENTAL
Intervention: Oral vancomycin (125 mg, four times a day) for 12 weeks
Number of subjects: 29
Study: 25642527

Group type: EXPERIMENTAL
Intervention: Patient-centred structured assessment linked to evidence-based treatment algorithms in 15 intervention services.
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: General Health Questionnaire‐12 at 6 months for psychological outcomes.
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Functional outcomes for patients and outcomes for carers measured through self-completed postal questionnaires at 6 and 12 months.
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of the intervention.
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: 22-item Longer-term Unmet Needs after Stroke (LUNS) questionnaire.
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Qualitative investigation with 22 patients and carers.
Number of subjects: 1008
Study: 23726776

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy / Interpersonal therapy
Number of subjects: 125
Study: 22043930

Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 17965146

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus deep brain stimulation (DBS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Medically treated patients with PD
Number of subjects: 23
Study: 16035957

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VIBES
Number of subjects: 0

Group type: COMPARATOR
Intervention: HAMD
Number of subjects: 0
Study: 12826855

Group type: EXPERIMENTAL
Intervention: Remifentanil at 0.1 microg x kg‐1 x min‐1
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: S-ketamine at 5 microg x kg‐1 x min‐1
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Clonidine at 2 microg/kg for 5 min
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 13
Study: 11122033

Group type: EXPERIMENTAL
Intervention: Topical tazarotene gel with narrowband UVB (311 nm)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Topical calcipotriol with narrowband UVB (311 nm)
Number of subjects: 10
Study: 9382235

Group type: EXPERIMENTAL
Intervention: Epidural morphine with 0.1 mg of clonidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular intramuscular morphine
Number of subjects: 60
Study: 1397240

Group type: EXPERIMENTAL
Intervention: Induction and consolidation chemotherapy with weekly parenteral vincristine, adriamycin, l‐asparaginase and daily oral prednisone (VAAP)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Maintenance therapy for 3 years consisting of daily 6‐mercaptopurine, weekly methotrexate, and monthly intrathecal chemotherapy
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Drug intensification comprising either vincristine, adriamycin and l‐asparaginase (VAA) or cyclophosphamide, vincristine, cytosine arabinoside and prednisone (COAP)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CNS prophylaxis
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Overall treatment protocol
Number of subjects: 46
Study: 3900932

Group type: EXPERIMENTAL
Intervention: Experimental nursing intervention group (8 visits over 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived difficulty in following a diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge of disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived severity of symptoms
Number of subjects: 0
Study: 31601541

Group type: EXPERIMENTAL
Intervention: NYVAC vector followed by NYVAC vector and gp120 Env protein (T1)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Four doses of NYVAC vector and gp120 Env protein (T2)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Two doses of DNA vector followed by two doses of NYVAC vector and gp120 Env protein (T3)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Two doses of DNA vector and gp120 Env protein followed by two doses of NYVAC vector and gp120 Env protein (T4)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (C1, C2, C3, C4)
Number of subjects: 96
Study: 30518042

Group type: EXPERIMENTAL
Intervention: Active image-assisted five-day food records (FR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Regular five-day food records (FR)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Image-assisted food records
Number of subjects: 22

Group type: COMPARATOR
Intervention: Regular food records
Number of subjects: 22
Study: 27314448

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bevacizumab (400 mg absolute)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 25042605

Group type: EXPERIMENTAL
Intervention: THRIVES intervention (patient report cards, phone text messaging, educational video, coordination of posthospitalization care)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: THRIVES intervention
Number of subjects: 400
Study: 22425243

Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration (SR‐WBV) training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 20